Verastem

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rolling NDA submission of avutometinib + defactinib for the treatment of patients with low-grade serous ovarian cancer is expected in the 1st half of 2024, with possible commercialization in 2025. Results from two studies, RAMP-203 and RAMP-204, each using avutometinib with two different types of KRAS G12C inhibitors for the treatment of KRAS G12C NSCLC, expected mid-2024. The global non-small cell lung cancer market is expected to reach $38.8 billion by 2030; About 13% of NSCLC patients have the KRAS G12C mutation.

Verastem: Other Catalysts In 2024 Beyond NDA Rolling Submission Of Defactinib

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today outlined key 2024 strategic priorities and upcoming catalysts to support advancement of its clinical programs in RAS pathway-driven cancers. “We have made significant progress in our commitment to advancing new solutions for RAS pathway-driven cancers and look forward to an exciting and catalyst-filled year ahead. With plans to submit an NDA.

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers

Verastem's (VSTM) avutometinib/Lumakras combination therapy gets the FDA's Fast Track designation to treat KRAS G12C-mutant metastatic NSCLC patients. The stock gains 8% in response.

Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Verastem Oncology's investigational RAF/MEK clamp, avutometinib, in combination with Amgen's KRAS G12C inhibitor, LUMAKRASTM (sotorasib), for the treatment of patients with KRAS G12C-mutant metastatic non-small cell lung cancer (NSCLC) who have receive.

Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

New York, N.Y., January 12, 2024 – In concert with Cervical Health Awareness Month, PRISM MarketView has added Verastem, Inc., a biopharmaceutical company focused on the development and commercialization of new medicines for patients combating various types of cancer to its Emerging Women's Health Index.

PRISM MarketView Announces the Addition of Verastem to Emerging Women's Health Index

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference on Thursday, January 18, 2024 at 4:00 p.m. ET. To access the live webcast of the fireside chat, please contact your B. Riley Securities sales representative. Following the event, an archived replay of the fi.

Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a potential best-in-class KRAS G12D oral inhibitor as the lead program of its discovery and development collaboration with GenFleet Therapeutics (“GenFleet”). “We are pleased to announce this oral KRAS G12D inhibitor with a potential best-in-class profile as the lead program from our collaboration with GenFleet supp.

Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics

Ouster, Inc

TPI Composites

As horror film fans know, there's safety in numbers but robust profitability may be more closer to the domain of uncommon stocks to buy for growth. Don't get me wrong – if you find yourself facing the market equivalent of a hockey-mask-wearing villain, you should probably consider the tried-and-true strength-in-numbers narrative.

3 Off-the-Beaten-Path Stocks Poised for Substantial Growth

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that it has initiated its international confirmatory Phase 3 RAMP 301 trial (GOG-3097; ENGOT-ov81/NCRI), evaluating the combination of avutometinib and defactinib versus standard chemotherapy or hormonal therapy for the treatment of recurrent low-grade serous ovarian cancer (LGSOC). “Patients and treating physicians.

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

EyePoint Pharmaceuticals

Syros Pharmaceuticals

If the first rule in the film “Fight Club” is to not talk about fight club, then the same rule applies to penny stocks with potential: you do not talk about these penny stocks with upside. To clarify, the ideas present tremendous risks.

Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential

Iovance Biotherapeutics

Precigen

In this market cycle that we are experiencing, new opportunities arise to take advantage of over the next few years. There is no better way to take advantage of these opportunities than through penny stocks.

3 Penny Stocks to Buy to Turn $1 into $100: November 2023

Verastem (VSTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy

BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the launch of the new healthcare professional component of Let's Talk About LGSOC, designed to support clinicians in the diagnosis and management of low-grade serous ovarian cancer (LGSOC). Let's Talk About LGSOC provides detailed information about the unique clinical, histopathological, and molecular features of LGSOC, current Na.

New Healthcare Professional Component of Let's Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach

An application for Accelerated Approval of avutometinib + defactinib for low-grade serous ovarian cancer patients is expected in the first half of 2024. The ongoing RAMP-301 study is being done to keep avutometinib + defactinib for LGSC on the market or to convert Accelerated Approval to Full Approval. Company entered into a collaboration agreement with GenFleet Therapeutics to expand its pipeline and strengthen its position in the RAS driven cancer pathway space.

Verastem: Potential Accelerated Approval Filing In H1 2024

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the third quarter ending September 30, 2023 and highlighted recent progress. “In the third quarter, we presented additional data with robust levels of response from a planned subgroup analysis of the RAMP 201 study supporting the role of avutometinib and defactinib as a potential treatment option for LGSOC rega.

Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

BOSTON--(BUSINESS WIRE)-- #LGSOCPatientImpactSurvey--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced results of the first-ever LGSOC Patient Impact Survey that reveal the particular challenges with diagnosis, disease management and mental, physical, and emotional well-being experienced by people living with low-grade serous ovarian cancer (LGSOC)*.1 This multi-national, online survey was conducted by The Harris Poll on behalf of.

First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today results of the efficacy and safety of avutometinib and defactinib in recurrent low-grade serous ovarian cancer (LGSOC) following prior systemic therapy. The results of this planned subgroup analysis of Part A of the Phase 2 RAMP 201 (ENGOT-ov60/GOG-3052) trial were presented as a late-breaking abstract in an oral pr.

Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today new executive leadership team appointments in advance of the Company's potential commercial launch of avutometinib in combination with defactinib in low-grade serous ovarian cancer (LGSOC) and to support the advancement of its broader development program in RAS pathway-driven cancers. "These leadership appointments.

Verastem Oncology Strengthens Executive Leadership Team with Key Appointments

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today the initial safety, pharmacokinetics and recommended Phase 2 dose (RP2D) in the RAMP 203 trial evaluating the safety, tolerability and efficacy of avutometinib in combination with sotorasib in patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC). The results will be presented at the AACR-NCI-EORTC Inter.

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer

Verastem is a biotechnology company focused on developing novel agents for solid tumors, with its main candidate being avutometinib. Avutometinib is being studied in various cancers, driven by RAS pathway activation, with promising early results in relapsed/refractory low-grade serous ovarian carcinoma. Verastem has sufficient cash to reach a new milestone in 2024 or early 2025, but more data is needed to determine if avutometinib is a viable solution in solid tumor oncology.

Verastem: Signs Of Life For A Beaten-Down Equity

BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the presentation of scientific background and clinical trial updates on the avutometinib and defactinib programs at the 5th Annual RAS-Targeted Drug Development Summit in Boston, Massachusetts. The updates are part of two oral presentations by Jonathan Pachter, PhD, Chief Scientific Officer and Louis Denis, MD, Chief Medical Offic.

Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit

Gold Royalty Corp

LuxUrban Hotels Inc

When discussing penny stocks to buy, no one should be under any illusion: this sector presents extreme dangers. And it's not just about the severity and acceleration of losses when getting things wrong.

3 Penny Stocks That Can Triple Your Money in the Next 12 Months

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company has entered into a discovery and development collaboration with GenFleet Therapeutics (“GenFleet”) to advance three oncology discovery programs targeting RAS pathway-driven cancers. The collaboration, which builds on the strengths of both Companies in oncology small molecule drug development, enable.

Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the second quarter ending June 30, 2023 and highlighted recent progress. “We made significant advancements in the second quarter, including presenting positive results from the RAMP 201 trial of avutometinib and defactinib in recurrent LGSOC and finalizing the design of the confirmatory Phase 3 trial. Both are.

Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that Dan Paterson, President and Chief Operating Officer, has been promoted to President and Chief Executive Officer (CEO). Brian Stuglik will retire from the CEO role and remain a member of the Board of Directors. These changes will be effective August 1, 2023, allowing for a smooth leadership transition. “On behal.

News for Verastem Stock (VSTM)